title: Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
authors.forename: Biju
authors.initials: B
authors.lastname: Krishnan
authors.forename: Monica
authors.initials: M
authors.lastname: Else
authors.forename: Geir E
authors.initials: GE
authors.lastname: Tjonnfjord
authors.forename: Bruno
authors.initials: B
authors.lastname: Cazin
authors.forename: Dennis
authors.initials: D
authors.lastname: Carney
authors.forename: John
authors.initials: J
authors.lastname: Carter
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Daniel
authors.initials: D
authors.lastname: Catovsky
authors.forename: Mark
authors.initials: M
authors.lastname: Ethell
authors.forename: Estella
authors.initials: E
authors.lastname: Matutes
authors.forename: Claire E
authors.initials: CE
authors.lastname: Dearden
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab